Strategy for Uptake of Processes for Recognizing and Responding to Acute Kidney Injury (SUPPORT AKI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03564314|
Recruitment Status : Active, not recruiting
First Posted : June 20, 2018
Last Update Posted : May 5, 2021
|Condition or disease||Intervention/treatment||Phase|
|Acute Kidney Injury||Other: SUPPORT AKI Clinical Decision Support||Not Applicable|
Overview: Cluster-randomized stepped-wedge trial to evaluate the impact of implementing a clinical decision support initiative for early recognition and management of hospital-acquired AKI.
Study Population: Adult patients hospitalized on surgical units in Alberta who develop acute kidney injury will be eligible if not already receiving dialysis.
Intervention: The multidimensional clinical decision support intervention consists of: (1) electronic and non-computerized tools for early recognition of AKI, (2) educational program for clinical staff, (3) decision support resources and guidance for the management of AKI and consultation with specialists.
Study Design: Using a stepped-wedge design, eight general and vascular surgery unit clusters in Calgary (Foothills Medical Centre, Peter Lougheed Centre) and Edmonton (University of Alberta Hospital, Grey Nuns Community Hospital), Alberta will be randomly ordered to be sequentially introduced to the clinical decision support intervention. The pre-implementation period will include all patients admitted to the participating hospital units in the year before the random timing of introduction of the initiative on each participating unit. The post-implementation study cohort will include patients admitted in the year after the random timing of introduction of the initiative on each unit. Analysis of processes of care and outcomes will focus on patients on these units who develop AKI during the pre- and post-implementation time periods (i.e. are eligible to receive care under the AKI decision support initiative). Additionally, health care providers (e.g. physicians, nursing staff, pharmacists) who have direct experience with the clinical decision support tools and processes will be invited to participate in the surveys and interviews pre- and post-implementation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1206 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Strategy for Uptake of Processes for Recognizing and Responding to Acute Kidney Injury|
|Actual Study Start Date :||March 13, 2017|
|Actual Primary Completion Date :||January 31, 2020|
|Estimated Study Completion Date :||December 31, 2021|
Experimental: SUPPORT AKI Clinical Decision Support
Multidimensional clinical decision support intervention consisting of education and tools to support early recognition and management of AKI, including guidance on fluid therapies, medication management, investigation, and consultation with specialists.
Other: SUPPORT AKI Clinical Decision Support
Surgical units will receive a multidimensional clinical decision support intervention consisting of: (1) electronic and non-computerized tools to alert for early recognition of AKI, (2) educational program for physicians and nursing staff, (3) decision support tools with guidance on fluid therapies, medication management, investigations for AKI, and consultation with specialists.
No Intervention: Control
Usual care provided to patients with AKI on surgical units.
- Progression of AKI [ Time Frame: From date of AKI onset to discharge from hospital, assessed up to 30 days ]Incidence of progression of AKI to higher AKI stage (including progression to dialysis or death)
- Length of AKI hospital stay, days [ Time Frame: From date of AKI onset to discharge from hospital, assessed up to 30 days ]Mean length of hospital stay from acute kidney injury to discharge
- Resource use for AKI [ Time Frame: Duration of index hospital admission, assessed up to 30 days ]Mean total health care costs of hospital care during the index admission
- Time to initial response to AKI [ Time Frame: From AKI onset up to 48 hours following AKI onset ]Time from AKI onset to clinical response with fluid or medication management intervention
- Volume intervention (change in fluid or diuretic order) for AKI [ Time Frame: Within 48 hours following AKI onset ]New or modified intravenous fluid or diuretic order
- Adverse medication exposure [ Time Frame: Within 48 hours following AKI onset ]Dose modification or suspension or a medication that may cause AKI or that is cleared by the kidney
- Medical consultation for AKI [ Time Frame: Within 7 days of AKI onset ]Consultation with nephrology or general internal medicine
- Change in estimated Glomerular Filtration Rate (eGFR) [ Time Frame: From most recent baseline eGFR measurement prior to AKI onset to eGFR measurement closest to 3 months after AKI onset ]The difference in eGFR from baseline to 3 months after development of AKI
- Mortality [ Time Frame: Within 30 days of AKI onset ]All cause mortality
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03564314
|Peter Lougheed Centre|
|Calgary, Alberta, Canada, T1Y6J4|
|Foothills Medical Centre|
|Calgary, Alberta, Canada, T2N2T9|
|University of Alberta Hospital|
|Edmonton, Alberta, Canada, T6G2B7|
|Grey Nuns Community Hospital|
|Edmonton, Alberta, Canada, T6L5X8|
|Principal Investigator:||Matthew T James, MD, PhD||Associate Professor|